Is ENDP a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

898 people get ENDP articles and Market Currents by email alert.

Get email alerts on ENDP »

HEADLINES:

FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer
Cory Renauer • Mon, May 20 • 2 Comments
Last Week's 13D/G Filings By Leading Fund Managers In Healthcare And Technology
GuruFundPicks • Thu, May 16
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone

PR Newswire (May 10, 2013)
Endo Health Solutions Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
Endo Reports First Quarter Financial Results

PR Newswire (May 7, 2013)
Weak Quarter At Auxilium Overshadows Execution On Long-Term Strategy
PropThink • Wed, May 1 • 3 Comments
FDA Bars Old OxyContin Generics: Read-Through To Continue Boosting Endo
PropThink • Wed, Apr 17 • 1 Comment
Endo to Announce First Quarter 2013 Financial Results on May 7, 2013

PR Newswire (Apr 15, 2013)
Acadia Pharmaceuticals Implies Sanuwave Could Triple On New Study Design
Nouvelle Asset Management • Fri, Apr 5 • 4 Comments
VIX - Options Volatility And Market Sonar: Wednesday Recap
Erick McKitterick • Wed, Apr 3 • 17 Comments
Endo Health's New Exec Expected To Swing Right Into Action
PropThink • Wed, Apr 3 • 1 Comment
Endo Health's New CEO To Reveal Strategy: Good News For Investors?
OneMedPlace • Sun, Mar 31
Endo Health's New CEO Will Be Revealing His Strategy - Good News For Investors?
PropThink • Thu, Mar 28 • 2 Comments
New CEO From Valeant May Mean Endo Takeover Imminent
Stock Traders Daily • Thu, Mar 7
Endo Health Solutions to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Mar 5, 2013)
Jazz Pharmaceuticals: Music To Our Ears
Capital Traders Group • Sun, Mar 3 • 3 Comments
Endo Health Solutions Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
VIX - Options Volatility And Market Sonar: Wednesday Recap
Erick McKitterick • Thu, Feb 28 • 36 Comments
Endo Reports Fourth Quarter Financial Results And Reaffirms 2013 Financial Guidance

PR Newswire (Feb 28, 2013)
4 Must Read Healthcare Headlines Heading Into March
D. Mero • Tue, Feb 26 • 9 Comments

To learn more about Seeking Alpha Pro, click here.

FDA Bars Old OxyContin Generics: Read-Through To Continue Boosting Endo
PropThink • Wed, Apr 17 • 1 Comment
Endo Health's New Exec Expected To Swing Right Into Action
PropThink • Wed, Apr 3 • 1 Comment
Endo Health's New CEO To Reveal Strategy: Good News For Investors?
OneMedPlace • Sun, Mar 31
Endo Health's New CEO Will Be Revealing His Strategy - Good News For Investors?
PropThink • Thu, Mar 28 • 2 Comments
New CEO From Valeant May Mean Endo Takeover Imminent
Stock Traders Daily • Thu, Mar 7
Endo To Become The Next Valeant - Or Part Of Valeant
PropThink • Mon, Feb 25
Endo Health Solutions - Opana Story De-Emphasized, Buyout Re-Emphasized
PropThink • Fri, Feb 8
Everybody Wins If Endo Health Is Acquired By Warner Chilcott Or Valeant
PropThink • Tue, Feb 5 • 1 Comment
Endo Health A Buyout Target: Valeant The Lead Suspect And Moves Quickly
PropThink • Thu, Jan 31
Endo Health Solutions Clears Out The Bad News, New Money Ready To Enter
PropThink • Fri, Jan 4 • 1 Comment
'Trouble Is Opportunity' - Endo Fallout Is Worth A Look
PropThink • Thu, Dec 13, 2012
This Cheap Drugmaker Beats Estimates And Is Ready To Move Higher
Bret Jensen • Tue, Aug 7, 2012 • 1 Comment
This Cheap Drug Stock Has New Insider Buying And Technical Support
Bret Jensen • Sun, Jun 17, 2012 • 3 Comments
Endo Pharmaceuticals Playing An Unconventional Hand
Stephen Simpson • Mon, Feb 27, 2012 • 2 Comments
Why I Picked Up Endo Pharmaceuticals At Under $35
Bret Jensen • Sun, Feb 19, 2012 • 19 Comments
Endo Pharma Looking for Action
Zacks Investment Research • Wed, May 18, 2011
Endo Makes $2.9B Device Play With American Medical Systems Acquisition
The Burrill Report • Thu, Apr 14, 2011 • 1 Comment
Endo Pharma Takes Over Privately Held Qualitest for $1.2 Billion
Zacks Investment Research • Fri, Dec 3, 2010
Endo Pharmaceuticals: Q3 Results Top Estimates; Upbeat on Growth
Proactive Investor • Mon, Nov 1, 2010
Endo's Latest Acquisition Builds Out Pain Franchise, Generics Lineup
The Burrill Report • Sun, Oct 3, 2010

FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer
Cory Renauer • Mon, May 20 • 2 Comments
Last Week's 13D/G Filings By Leading Fund Managers In Healthcare And Technology
GuruFundPicks • Thu, May 16
Weak Quarter At Auxilium Overshadows Execution On Long-Term Strategy
PropThink • Wed, May 1 • 3 Comments
Acadia Pharmaceuticals Implies Sanuwave Could Triple On New Study Design
Nouvelle Asset Management • Fri, Apr 5 • 4 Comments
VIX - Options Volatility And Market Sonar: Wednesday Recap
Erick McKitterick • Wed, Apr 3 • 17 Comments
Jazz Pharmaceuticals: Music To Our Ears
Capital Traders Group • Sun, Mar 3 • 3 Comments
VIX - Options Volatility And Market Sonar: Wednesday Recap
Erick McKitterick • Thu, Feb 28 • 36 Comments
4 Must Read Healthcare Headlines Heading Into March
D. Mero • Tue, Feb 26 • 9 Comments
Maverick Capital's Largest Small-Cap Stock Picks
Insider Monkey • Thu, Feb 7
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Jan 31 • 1 Comment
4 Biotech Names With Major Market Potential: Michael Higgins
Life Sciences Report • Thu, Dec 20, 2012 • 5 Comments
3 Small-Cap Biopharmas With Trade Catalysts And Speculation Investment Potential
Scott Matusow • Tue, Dec 4, 2012 • 21 Comments
5 Healthcare Companies With Recent Insider Buying
Markus Aarnio • Thu, Nov 15, 2012
Zogenix: Upcoming Catalysts Should Provide Upside
Scott Matusow • Tue, Oct 2, 2012 • 26 Comments
BioDelivery Sciences International: Making The Most Of This Small-Cap Opportunity
Adin Dobkin • Fri, Sep 7, 2012
Zalicus: Pain Free Investing
Icarus Falling • Fri, Sep 7, 2012 • 37 Comments
Uncertainty Is The Trade-Off For Salix's Appealing Price
Stephen Simpson • Tue, Aug 14, 2012 • 5 Comments
The Party's Still On: Watson's Rise Is Only Halfway There
Daniel Shvartsman • Tue, Jul 31, 2012 • 1 Comment
Short Squeeze Draws Closer For Questcor
Marwaan Karame • Thu, Jul 19, 2012 • 19 Comments
Fund Holdings For 3 Healthcare Stocks, And 4 Other Sells
GuruFundPicks • Mon, Jun 18, 2012

Endo Health Solutions Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
Endo Health Solutions Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Endo Health Solutions' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 5, 2012
Endo Health Solutions' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012
Endo Pharmaceuticals Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 1, 2012
Endo Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Fri, Feb 24, 2012
Endo Pharmaceuticals at 2011 Credit Suisse Annual Health Care Conference Call Transcript
Fri, Nov 11, 2011
Endo Pharmaceuticals Holdings' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Thu, Oct 27, 2011
Endo Pharmaceuticals Holdings CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Aug 9, 2011
Endo Pharmaceuticals Holdings Inc. Q1 2009 Earnings Call Transcript
Wed, Apr 29, 2009
Endo Pharmaceuticals Holdings, Inc. Q4 2008 Earnings Call Transcript
Fri, Feb 27, 2009
Endo Pharmaceuticals Holdings Inc. Q3 2008 Earnings Conference Call Transcript
Thu, Oct 30, 2008
Endo Pharmaceuticals Holdings, Inc. Q2 2008 Earnings Call
Thu, Jul 31, 2008
Endo Pharmaceuticals Holdings, Inc. Q1 2008 Earnings Call Transcript
Wed, Apr 30, 2008
Endo Pharmaceuticals Holdings, Inc. Q4 2007 Earnings Call Transcript
Sun, Feb 24, 2008
Endo Pharmaceuticals Holdings Inc. Q3 2007 Earnings Call Transcript
Fri, Nov 2, 2007

Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone

PR Newswire (May 10, 2013)
Endo Reports First Quarter Financial Results

PR Newswire (May 7, 2013)
Endo to Announce First Quarter 2013 Financial Results on May 7, 2013

PR Newswire (Apr 15, 2013)
Endo Health Solutions to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Mar 5, 2013)
Endo Reports Fourth Quarter Financial Results And Reaffirms 2013 Financial Guidance

PR Newswire (Feb 28, 2013)
Rajiv De Silva Named President and CEO of Endo Health Solutions

PR Newswire (Feb 25, 2013)
Endo to Announce Fourth Quarter 2012 Financial Results on February 28, 2013

PR Newswire (Feb 13, 2013)
After-Hours Buzz: CSTR, PRGS & More

at CNBC.com (Jan 3, 2013)
Endo Health Solutions Reaffirms 2012 Adjusted Earnings Per Share Outlook and Provides 2013 Financial Guidance

PR Newswire (Jan 3, 2013)
Endo Health Solutions Comments on Dismissal of Suit Against FDA

PR Newswire (Dec 19, 2012)
Endo Health Solutions Announces CEO Transition Plan

PR Newswire (Dec 12, 2012)
Endo Health Solutions Launches 7.5mg and 15mg strengths of Reformulated, Designed to be Crush-Resistant, OPANA® ER

PR Newswire (Dec 11, 2012)
Endo Health Solutions Sues FDA to Protect Consumers from Non-Tamper Resistant Oxymorphone

PR Newswire (Nov 30, 2012)
Why Samsung Stock Surge Won't Fizzle Out Like Apple's

at CNBC.com (Nov 22, 2012)
Here Are Small Cap Values: Gabelli

at CNBC.com (Nov 21, 2012)
Endo Health Solutions Supplements Citizen Petition With Preliminary Data Showing a 59% Drop in Abuse of the Reformulated, Designed to be Crush-Resistant, OPANA® ER

PR Newswire (Nov 13, 2012)
Endo Health Solutions to Present at 2012 Annual Credit Suisse Healthcare Conference

PR Newswire (Nov 8, 2012)
Endo Health Solutions to Present at Jefferies 2012 Global Healthcare Conference

PR Newswire (Nov 7, 2012)
Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance

PR Newswire (Nov 5, 2012)
Endo to Announce Third Quarter 2012 Financial Results on Nov. 5, 2012

PR Newswire (Oct 22, 2012)

ENDP vs. ETF Alternatives

Company Description

We are a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of branded and generic prescription pharmaceuticals used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer, and the early onset of puberty in... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 12:20 PM Endo Health Solutions (ENDP -2.6%) appears to have stabilized today, albeit lower, following a couple of trading halts on volatility just prior to Friday's close after the FDA denied its petition to halt generic competition to its painkiller Opana ER on safety grounds. The ruling will mean a big hit to earnings next quarter, and likely lead exploring options to mitigate the damage. Jefferies says the FDA was wrong, and acted "irrationally inconsistent" in its decision. Nonetheless, the firm lowers its price target on the shares from $47.00 to $37.00. Comment! [Healthcare, On the Move, Earnings]
Friday, May 10, 5:47 PM After-hours top gainers, as of 5:30 p.m.: ENDP +3.6%. NVAX +2.8%. GRFS +2.7%. REE +2.6%. IMRS +2.4%.
AftTer-hours top losers: ET -4.0%. APTS -3.7%. SYNC -3.6%. SSRI -2.7%. VG -2.5%. Comment! [On the Move]
Friday, May 10, 4:15 PM Today's decision by the FDA on Endo's (ENDP -5.3%) Opana ER puts to rest an aggressive campaign begun last October by the drug developer to keep generic versions off the market. In the end, the agency comes full circle, reiterating that the original formulation of Opana ER was not withdrawn for reasons of safety or effectiveness. Therefore, generic versions of the original formulation can continue to be approved and marketed. Following a brief resumption of trading just before the closing bell, the stock has since been halted a second time. Comment! [Healthcare, On the Move]
Friday, May 10, 3:36 PM Shares of Endo Health (ENDP -3.6%) trade lower following a brief halt after the FDA denies its petition to block generic versions of its Opana ER. ZGNX +2.1%, IPXL +8.4%. Comment! [Healthcare, On the Move]
Tuesday, May 7, 4:02 PM Endo Health (ENDP +0.8%) is set to finish in the green today, despite posting a mixed Q1. Net earnings swung to a profit amid fewer write-downs and other items, as well as a modest revenue increase on strong generic sales growth. Generic sales +23% at $178M, while branded-pharmaceutical sales declined 2% to $358M. Lidoderm sales dropped 11%, mostly owing to its supply agreement with Actavis (ACT). Sales of Opana ER slumped 31% as sales continue to lag following a disruption early last year resulting from the closing of a Novartis (NVS) plant. Comment! [Healthcare, Earnings]
Tuesday, May 7, 7:03 AM Endo Health (ENDP): Q1 EPS of $1.09 beats by $0.01. Revenue of $709M (+3% Y/Y) misses by $28.79M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
Tuesday, April 16, 7:34 PM Endo Health Solutions (ENDP) trades higher after hours as the FDA says it won't approve generic copies of the old version of OxyContin. The first patent on the old version expired today, and drug makers had been lining up to make copies. But the newer, reformulated OxyContin was found to be tougher to crush, break or dissolve, the FDA said, and "the benefits of the old formulation no longer outweigh its risks." Shares +5.6% AH. Comment! [Healthcare, On the Move]
Tuesday, April 16, 5:30 PM After-hours top gainers, as of 5:15 p.m.: BPFH +14%. VXZ +9%. ENDP +6%. NMR +3%. HL +2%.
After-hours top losers: PNFP -11%. QNST -8%. URI -4%. TMO -4%. YHOO -4%. Comment! [On the Move]
Tuesday, April 16, 9:19 AM Endo Health's (ENDP) Aveed testosterone injection, which will be the subject of an FDA advisory panel vote this week, is associated with "concerning" post-injection reactions which, in some cases, led to hospitalizations and resuscitations. (Reuters) Comment! [Healthcare]
Thursday, February 28, 5:05 PM Endo Health (ENDP): Q4 EPS of $1.62 beats by $0.08. Revenue of $801M misses by $6.98M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 28, 12:10 AM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU Comment! [Earnings]
Wednesday, February 27, 5:35 PM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU 1 Comment [Earnings]
Tuesday, February 26, 10:03 AM The award of $3.35M against J&J (JNJ +0.8%) over its vaginal mesh in a case involving a South Dakota patient could have an impact on other suits against the company and rival manufacturers C.R. Bard (BCR +0.3%), Boston Scientific (BSX -0.3%) and Endo Health (ENDP +0.3%). Around 11,000 claims have been consolidated into five cases that are pending in West Virginia. Comment! [Healthcare]
Monday, February 25, 11:34 AM Endo Health Solutions (ENDP +7.1%) names Rajiv De Silva , who had been president of Valeant Pharmaceuticals International (VRX +0.6%), as it's president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds its retiring current CEO David Holveck. The announcement eclipses a downgrade by Jefferies to Underweight, citing persistent uncertainty over the extent of generic competition on Opana ER and Lidoderm. Comment! [Healthcare, On the Move]

The Wall Street Transcript
Endo Health Solutions ($ENDP) Revenue to Shrink due to Lidoderm and Opana ER Generic Competition- http://su.pr/2Sx3Rf
May 3, 10:45 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for April 17 2013 | $ARMH $ASML $ENDP $VVUS | SharePlanner http://bit.ly/12mdW8S
Apr 17, 9:03 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
just published part 1 of our April Biotech binary event watch : http://bit.ly/ZmquIg $AGN, $THRX, $ENDP, $SCMP, $GILD
Apr 10, 7:37 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (4/2/13): $DIS, $DVA, $ECL, $ENDP, $HNT, $ININ, $LHCG, $MKL, $OMC, $OPEN, $ORLY, $SAM, $SBUX
Apr 3, 1:03 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

SKS1586
Sold $EXC, $ENDP to keep Profit & Bought $SWC, $SWKS, $CCJ, $EXPD.
Feb 26, 2:16 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MagicDiligence
Stocks moving in and out of Magic Formula Investing this week. $ENDP $JOY $LMCA and others. http://bit.ly/13SLtrK
Jan 20, 9:35 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MagicDiligence
Stocks moving in and out of Magic Formula Investing this week $GCI $ENDP $LMT and others http://bit.ly/WdYF9o
12/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Stone Fox Capital
$ENDP... bad sign when guidance is pulled and the CEO plans to retire.
12/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MagicDiligence
Been a while since Endo Health $ENDP has been in MFI. Diversified but smaller hlthcare firm - branded, generic, now devices. Worth a look.
10/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
$SHLM $ENDP $XEC top buys on TrendExhaustion right now! http://bit.ly/HbSeYM
6/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Jacob Wolinsky
America's Best Companies are Cheap http://bit.ly/sbXkGk $ABT AVP $BBY $CVX $ENDP $EZPW $FISV GME $HPG $INTC IR ItW JNJ $MDT SYK TEVA LLL
12/19/11
Reply (2)

• !Report Abuse
View all 2 replies
Clayton Rulli: BBY sux.. TEVA an american company? Its based in Israel
12/19/11
• !Report Abuse
Jacob Wolinsky: Its an ADR
12/19/11
• !Report Abuse
Add a reply...

140 characters

ENDP Endo Health Solutions Inc.

ENDP

Endo Health Solutions Inc.